Duration of Effective Antibody Levels After COVID-19

Andrea T. Cruz, MD, MPH, and Steven L. Zeichner, MD, PhD

DOI: 10.1542/peds.2021-052589

Journal: Pediatrics

Article Type: Solicited Commentary

Citation: Cruz AT, Zeichner S. Duration of effective antibody levels after COVID-19. Pediatrics. 2021; doi: 10.1542/peds.2021-052589

This is a prepublication version of an article that has undergone peer review and been accepted for publication but is not the final version of record. This paper may be cited using the DOI and date of access. This paper may contain information that has errors in facts, figures, and statements, and will be corrected in the final published version. The journal is providing an early version of this article to expedite access to this information. The American Academy of Pediatrics, the editors, and authors are not responsible for inaccurate information and data described in this version.
Duration of Effective Antibody Levels After COVID-19

Andrea T. Cruz, MD, MPH\textsuperscript{a} and Steven L. Zeichner, MD, PhD\textsuperscript{b}

\textbf{Affiliations:} \textsuperscript{a}Department of Pediatrics, Baylor College of Medicine, Houston, Texas and \textsuperscript{b}Departments of Pediatrics and Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia

\textbf{Address correspondence to:}

AT Cruz

Department of Pediatrics, Baylor College of Medicine
6621 Fannin Street, Suite A2210
Houston TX 77030

[acruz@bcm.edu]

832-824-5582

\textbf{Conflict of Interest Disclosures:} Both authors are associate editors for \textit{Pediatrics}.

\textbf{Funding/support:} No funding was secured for this study.

\textbf{Abbreviations:} COVID-19: coronavirus disease 2019; MIS-C: multisystem inflammatory syndrome in children; nAbs: neutralizing antibodies; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2

\textbf{Contributors’ Statement Page}

Dr. Cruz conceptualized the commentary, drafted the initial commentary, and reviewed and revised the manuscript.

Dr. Zeichner critically reviewed and revised the manuscript for important intellectual content.

Both authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
After having COVID-19, patients develop a humoral immune response thought to protect against reinfection, but antibody levels can decline over time. Understanding how long antibody levels remain high enough to prevent infection is important in understanding, absent vaccination, whether children may be vulnerable to COVID-19, and in modeling how COVID-19 spreads through the population.

The levels of antibodies capable of neutralizing the virus — neutralizing antibodies (nAbs) — provide a direct marker of a protective humoral immune response. nAbs can be measured directly by determining how well a patient’s serum inactivates virus when a known amount of virus is placed on cells in tissue culture — a plaque reduction neutralization test (PRNT). The remarkably safe and effective approved COVID-19 vaccines elicit potent antibody responses against portions of the virus mediating attachment to host cells and viral entry, the spike protein and its receptor binding domain (RBD). The concentration of antibodies a patient has against spike and RBD provides a marker of susceptibility to infection or reinfection.1-3

The study in *Pediatrics* by Bonfante and colleagues4 reports that preschool-aged children with asymptomatic or mildly symptomatic SARS-CoV-2 infection had high levels of nAbs and that these levels remained high for the duration of their 7–8-month follow-up period. In contrast, lower nAb levels and more transient nAb responses were seen in school-aged children and adults.
These findings are intriguing for several reasons. First, nAbs persisted in younger children at high levels for several months. This is in contrast to the experience with both adults and with non-SARS-CoV-2 coronavirus infections. One study found that after COVID-19 disease, only one-third of adults had detectable nAbs and, even in those patients, nAb levels decayed rapidly over a few months. For non-SARS-CoV-2 coronaviruses, nAbs wane within several months of infection, resulting in repetitive infections by many coronaviruses that cause a significant fraction of viruses causing common colds. Reasons for the enhanced persistence of nAbs in younger children is unclear. One explanation may be that the immune response in adults, who have had repetitive exposure to endemic coronaviruses, may target these prior viruses and may not respond as easily to SARS-CoV-2 as the relatively less experienced (and potentially more flexible) immune response seen in young children. This concept is called original antigenic sin (OAS). While OAS may result in a more robust response to viral strains previously encountered, antibodies made against a newly encountered coronavirus in patients who have had many coronavirus infections may bind suboptimally to strains with more antigenic drift.

The ability to generate an immune response in younger children was not contingent upon illness severity. In adults, several studies have shown that antibody responses were higher in more severely ill than in mildly ill patients. Given that up to 50% of children with SARS-CoV-2 have subclinical or mild symptoms, the ability to mount an immune response that yields good nAb levels for at least several months is reassuring, as vaccines remain unavailable to younger children. Even after vaccines are approved for the youngest children, barriers to vaccine uptake (including vaccine hesitancy and logistical barriers to widespread global distribution) mean that many children will not benefit from vaccination in the near future. As such, the data presented in
This study suggest that reinfection may be a less common occurrence, given the magnitude and durability of the antibody response.

This does **not** mean that children who have already had SARS-CoV-2 should remain unimmunized once vaccines are approved for younger children. Recent data from vaccinated individuals and convalescent adult cohorts indicate that nAb levels are highly correlated with immunity. The mean nAb levels seen after vaccination are higher than levels seen in convalescent adults. Levels of nAbs decay with time, so the efficacy of a vaccine will not remain static over time. This may be a reason that boosters will be necessary, and boosters may also be needed to target newer SARS-CoV-2 variants for which existing vaccines may provide inadequate protection. Another reason for previously infected individuals to be vaccinated is that neutralizing antibodies are only part of the host immune response. Immunoprotection may stem from other arms of the immune system, some of which may be more durable (e.g., memory B cell or T-cell responses). For example, one study evaluated how immunity to endemic coronaviruses may impact host response to SARS-CoV-2. They found that, while there was little evidence of cross-reactive SARS-CoV-2 serum antibodies, pre-existing memory B cells were activated during SARS-CoV-2 infection. The study by Bonfante and colleagues focused on the patients’ antibody responses to SARS-CoV-2, but it is important to remember that cellular immunity plays an important role in the ability of a patient to control SARS-CoV-2. To fully understand the durability immune responses of children to COVID-19 and how these differ from those in adults, it will be necessary to describe pediatric long-term cell-mediated immune responses in addition to humoral responses.
While many aspects of what comprises an effective immune response to SARS-CoV-2 require additional study, the work of Bonfante and colleagues advances our understanding, demonstrating a more durable (and likely effective) response in younger children. Since children constitute an important contribution to the spread of COVID-19 through the population, knowledge of the potential susceptibility of children to reinfection is important in modeling COVID-19 epidemiology.

References


Duration of Effective Antibody Levels After COVID-19
Andrea T. Cruz and Steven L. Zeichner
*Pediatrics* originally published online June 22, 2021;

**Updated Information & Services**
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/early/2021/06/18/peds.2021-052589.citation

**Permissions & Licensing**
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.aappublications.org/site/misc/Permissions.xhtml

**Reprints**
Information about ordering reprints can be found online:
http://www.aappublications.org/site/misc/reprints.xhtml
Duration of Effective Antibody Levels After COVID-19
Andrea T. Cruz and Steven L. Zeichner
*Pediatrics* originally published online June 22, 2021;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/early/2021/06/18/peds.2021-052589.citation